公开(公告)号：US20040198669A1

公开(公告)日：2004-10-07

申请号：US10403814

申请日：2003-03-31

申请人： COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH

发明人： Suman Preet Singh Khanuja ,  Jai Shanker Arya ,  Ranganathan Santha Kumar Tiruppadiripuliyur ,  Dharmendra Saikia ,  Harpreet Kaur ,  Monika Singh ,  Subhash Chandra Gupta ,  Ajit Kumar Shasany ,  Mahendra Pandurang Darokar ,  Santosh Kumar Srivastava ,  Madan Mohan Gupta ,  Subash Chandra Verma ,  Anirban Pal

IPC分类号： C07H015/06 ,  A61K031/704

CPC分类号： C07H15/06 ,  A61K31/704 ,  A61K45/06 ,  A61K2300/00

摘要： The present invention relates to a novel nitrile glycoside of Formula I named NIAZIRIDIN and to analogues and derivatives thereof. The present invention also relates to a process for the isolation of a novel nitrile glycoside of Formula I below named NIAZIRIDIN and its derivatives and analogues by bioactivity-guided fractionation from the pods of Moringa oleifera. The present invention particularly relates to the bioenhancing activity of the novel nitrile glycoside of Formula I below named NIAZIRIDIN and its derivatives and analogues in enhancing bioactivity of commonly used antibiotics such as rifampicin, tetracycline and ampicillin against Gram (null) and (null) bacteria. The biomolecule also enhances the absorption of drugs, vitamins and nutrients through the gastro-intestinal membrane increasing their bio-availability. Therefore niaziridin can be used in combination therapy with drugs and nutrients resulting in reduced drug associated toxicity, reduced cost and duration of chemotherapy. 1

摘要翻译： 本发明涉及名为NIAZIRIDIN的式I的新型腈糖苷及其类似物及其衍生物。 本发明还涉及一种通过生物活性指导的分离来自pod the的荚果分离下述式I的新型腈糖苷的方法，其命名为NIAZIRIDIN及其衍生物和类似物。 本发明特别涉及下述命名为NIAZIRIDIN及其衍生物和类似物的式I的新型腈糖苷增强常用抗生素如利福平，四环素和氨苄青霉素对革兰氏阳性（+）和（ - ）细菌的生物活性的生物增强活性。 生物分子还通过胃肠膜增强药物，维生素和营养素的吸收，增加其生物利用度。 因此，尼日吉林可以与药物和营养物联合使用，导致药物相关毒性降低，降低成本和化疗持续时间。

公开(公告)号：US20030119758A1

公开(公告)日：2003-06-26

申请号：US10312617

申请日：2002-12-27

发明人： Shozo Takechi

IPC分类号： A61K031/704 ,  C07H015/06

CPC分类号： C07H7/033

摘要： The present invention provides an amine salt of a lignan compound, i.e., null1-O-null4-(3,4-dimethoxyphenyl)-2-(3- ethylpentanoyl)-5,6,7-trimethoxy-3- (methoxycarbonyl)naphthalen-1-ylnull-beta-D- glucopyranosidenulluronic acid, which is useful as a medicament. The present invention also provides a method for purifying said lignan compound.

摘要翻译： 本发明提供木质素化合物的胺盐，即[1-O- [4-（3,4-二甲氧基苯基）-2-（3-乙基戊酰基）-5,6,7-三甲氧基-3-（甲氧基羰基 ）萘-1-基]-β-D-吡喃葡萄糖苷]糖醛酸，其可用作药物。 本发明还提供了一种纯化所述木酚素化合物的方法。

公开(公告)号：US20020022597A1

公开(公告)日：2002-02-21

申请号：US09939338

申请日：2001-08-24

申请人： TOYO SUISAN KAISHA, LTD.

发明人： Takayuki Yamazaki ,  Fumio Sugawara ,  Keisuke Ohta ,  Kazuyoshi Masaki ,  Kotaro Nakayama ,  Kengo Sakaguchi ,  Noriyuki Sato ,  Hiroeki Sahara ,  Tatsuya Fujita

IPC分类号： A61K031/7024 ,  C07H015/06

CPC分类号： C07H15/06 ,  C07H15/04

摘要： Novel sulforhamnosylacylglycerol derivatives represented by General Formula (1): 1 where R101 represents an acyl residue of a higher fatty acid and R102 represents a hydrogen atom or an acyl residue of a higher fatty acid. The derivatives represented by General formula (1) are useful as, a DNA polymerase inhibitor and an anticancer agent.

摘要翻译： 由通式（1）表示的新型磺基乳糖醛酸甘油衍生物：其中R101表示高级脂肪酸的酰基，R102表示氢原子或高级脂肪酸的酰基残基。 由通式（1）表示的衍生物可用作DNA聚合酶抑制剂和抗癌剂。